Moleculin Biotech regains Nasdaq bid price compliance after stock closes at $1.00+ for 10 days

Moleculin Biotech, Inc.

Nasdaq confirmed compliance with Listing Rule 5550(a)(2) effective Dec 15, 2025.
Cure based on closing bid price at or above $1.00 for 10 consecutive days ending Dec 12.
Previous deficiency notice from June 27, 2025 is now closed.

item 8.01

Moleculin Biotech, Inc. filing history →

Source: SEC EDGAR

accession 0001437749-25-038047

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.